Celldex Therapeutics, Inc. (CLDX) Receives $6.50 Consensus Target Price from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given an average rating of “Hold” by the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $6.50.

Several research firms recently issued reports on CLDX. HC Wainwright set a $10.00 target price on shares of Celldex Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. Cantor Fitzgerald reiterated a “buy” rating and issued a $9.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, September 26th. ValuEngine cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. BidaskClub cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Finally, Zacks Investment Research cut shares of Celldex Therapeutics from a “buy” rating to a “sell” rating in a research note on Monday, July 17th.

A number of large investors have recently bought and sold shares of CLDX. Teachers Advisors LLC raised its position in Celldex Therapeutics by 0.9% during the fourth quarter. Teachers Advisors LLC now owns 167,582 shares of the biopharmaceutical company’s stock worth $593,000 after acquiring an additional 1,433 shares during the period. Bank of New York Mellon Corp raised its position in Celldex Therapeutics by 1.1% during the first quarter. Bank of New York Mellon Corp now owns 538,156 shares of the biopharmaceutical company’s stock worth $1,943,000 after acquiring an additional 5,616 shares during the period. UBS Asset Management Americas Inc. raised its position in Celldex Therapeutics by 103.3% during the first quarter. UBS Asset Management Americas Inc. now owns 78,055 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 39,658 shares during the period. Parametric Portfolio Associates LLC raised its position in Celldex Therapeutics by 2.2% during the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock worth $238,000 after acquiring an additional 1,409 shares during the period. Finally, Raymond James Financial Services Advisors Inc. raised its position in Celldex Therapeutics by 26.2% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 6,000 shares during the period. Institutional investors own 56.69% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2017/10/11/celldex-therapeutics-inc-cldx-receives-6-50-consensus-target-price-from-analysts.html.

Shares of Celldex Therapeutics (CLDX) traded down 0.32% during mid-day trading on Friday, hitting $3.12. 795,782 shares of the stock traded hands. The firm has a 50 day moving average of $2.68 and a 200 day moving average of $2.77. Celldex Therapeutics has a 12 month low of $2.20 and a 12 month high of $5.02. The stock’s market cap is $400.42 million.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $1.21 million. During the same period in the prior year, the firm earned ($0.32) EPS. The business’s revenue for the quarter was up 175.5% on a year-over-year basis. On average, equities analysts expect that Celldex Therapeutics will post ($1.04) EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply